GlassScriptPhysician profile
Kimberly G Warnock
NPI 1568802049
$1,861.13
in general payments reported to CMS, 2019-2025
23 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $570 · 2024: $827 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $235.39 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cvrx, INC. | $210.20 | 2024 | Barostim Neo System |
| Abbott Laboratories | $197.55 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2, Cardiomems |
| Dexcom, INC. | $190.55 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $177.68 | 2022-2025 | Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.16 | 2023-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $103.74 | 2023-2025 | |
| Mylan Specialty L.P. | $83.67 | 2022-2024 | Yupelri |
| Amgen INC. | $80.69 | 2022-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $69.26 | 2023-2024 | Verquvo, Belsomra |
| Lilly USA, LLC | $62.23 | 2022-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $47.04 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $43.83 | 2023 | Quviviq |
| Impulse Dynamics (USA) INC. | $38.27 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $35.15 | 2024-2025 | Farxiga, Airsupra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.15 | 2023-2024 | |
| Esperion Therapeutics, INC. | $28.58 | 2025 | Nexletol |
| Viatris Specialty LLC | $24.84 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $23.55 | 2024 | Inspire |
| Scpharmaceuticals INC. | $20.99 | 2025 | |
| Sanofi Pasteur INC. | $19.46 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.77 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.38 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Warnock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.